Will the increased prevalence of nonalcoholic steatohepatitis (NASH) in the age of better hepatitis C virus therapy make NASH the deadlier disease?
Open Access
- 30 August 2011
- journal article
- editorial
- Published by Wolters Kluwer Health in Hepatology
- Vol. 54 (4) , 1118-1120
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: An international collaborative studyHepatology, 2011
- Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver diseaseHepatology, 2011
- Prevalence of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among a Largely Middle-Aged Population Utilizing Ultrasound and Liver Biopsy: A Prospective StudyGastroenterology, 2011
- Prevalence, Metabolic Features, and Prognosis of Metabolically Healthy Obese Italian IndividualsDiabetes Care, 2010
- Pioglitazone, Vitamin E, or Placebo for Nonalcoholic SteatohepatitisNew England Journal of Medicine, 2010
- Influence of ethnicity on histological differences in non-alcoholic fatty liver diseaseJournal of Hepatology, 2009
- Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver diseaseNature Genetics, 2008
- The Prevalence of Hepatitis C Virus Infection in the United States, 1999 through 2002Annals of Internal Medicine, 2006
- Reinitiation involving upstream ORFs regulates ATF4 mRNA translation in mammalian cellsProceedings of the National Academy of Sciences, 2004
- Long–Term Outcomes of Cirrhosis in Nonalcoholic Steatohepatitis Compared With Hepatitis CHepatology, 2003